Phase 2 trial of pembrolizumab-based therapy in previously treated extrapulmonary poorly-differentiated neuroendocrine carcinomas: Results of part B (pembrolizumab plus chemotherapy) Meeting Abstract
| Authors: | Chan, J. A.; Raj, N. P.; Aggarwal, R. R.; Hope, T. A.; Kolli, K. P.; Zhang, L.; Fattah, D.; Calabrese, S.; Grabowsky, J. A.; Perez, K.; Von Fedak, S.; DeMore, A.; Munster, P. N.; Dhawan, M.; Reidy-Lagunes, D.; Fong, L.; Bergsland, E. K. |
| Abstract Title: | Phase 2 trial of pembrolizumab-based therapy in previously treated extrapulmonary poorly-differentiated neuroendocrine carcinomas: Results of part B (pembrolizumab plus chemotherapy) |
| Meeting Title: | 14th Annual Multidisciplinary Neuroendocrine Tumor Medical Virtual Symposium of the North American Neuroendocrine Tumor Society (NANETS 2021) |
| Journal Title: | Pancreas |
| Volume: | 51 |
| Issue: | 3 |
| Meeting Dates: | 2021 Nov 4-6 |
| Meeting Location: | Virtual |
| ISSN: | 0885-3177 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2022-03-01 |
| Start Page: | E40 |
| End Page: | E41 |
| Language: | English |
| ACCESSION: | WOS:000819123700050 |
| PROVIDER: | wos |
| PUBMED: | 35584389 |
| DOI: | 10.1097/MPA.0000000000001979 |
| Notes: | Meeting Abstract: C-19 -- Located in section labeled "Clinical" -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work